SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining traction as a critical DeFi infrastructure provider, with the community highlighting its institutional-grade data integration, U.S. government partnerships, and a revenue-sharing model that includes token buybacks. Investors are increasingly focused on its role in the emerging Real World Asset (RWA) narrative and its potential for growth as a key decentralized oracle.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending as investors react to a major $125 million institutional funding round for Eightco Holdings, which features significant capital commitments from Bitmine and ARK Invest alongside a new board appointment for Chairman Tom Lee. The community is actively debating the company's broader pivot into AI and blockchain infrastructure, with many participants analyzing how these strategic partnerships and treasury holdings compare against Ethereum's recent market performance.

Coeur Mining, Inc. engages in the well-diversified, growing precious metals producer with a focus on generating sustainable, high-quality cash flow and returns from a balanced, prospective asset base in mining-friendly jurisdictions along with commitment to exploration and expansions. It operates through the following segments: Palmarejo, Rochester, Kensington, Wharf and Silvertip. The Palmarejo segment includes a gold-silver complex. The Rochester segment operates an open pit heap leach silver-gold mine in northwestern Nevada. The Kensington segment relates to an underground gold mine located north of Juneau, Alaska. The Wharf segment focuses on an open pit heap leach gold mine located near Lead, South Dakota. The Silvertip segment silver-zinc-lead exploration located in the state of Sonora in northern Mexico. The company was founded in 1928 and is headquartered in Chicago, IL.

Coeur Mining Inc

Coeur Mining is drawing heavy interest from traders as high short interest, record free cash flow, and a pending acquisition of New Gold fuel a potential breakout narrative. Community members remain focused on the stock's significant undervaluation relative to surging gold, silver, and copper prices, with many actively debating the impact of the upcoming merger and looking for strong moves to test year-to-date highs.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is generating significant buzz as traders speculate on potential institutional integration and its future role in emerging digital payment systems. The community remains deeply divided, with optimistic bulls eyeing long-term adoption catalysts while skeptics continue to caution against volatility and historical price patterns.

Almonty Industries, Inc. engages in mining, processing and shipment of tungsten concentrates. Its projects include Los Santos, Valtreixal, Almonty Korea Tungsten, Almonty Korea Moly, and Panasquiera. The company was founded on September 28, 2009 and is headquartered in Toronto, Canada.

Almonty Industries Inc

Almonty Industries is trending as investors bet on the company's critical role in a global 'tungsten supercycle,' driven by Chinese export restrictions and intensified defense-sector demand for non-PRC supply chains. Community discussion is heavily focused on the company's strategic move to secure Western supply independence, with many highlighting long-term potential as its Sangdong mine reaches commercial production.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is drawing significant investor interest as it approaches major clinical milestones and potential regulatory catalysts, with the community highlighting its strong cash position and the unique market opportunity of its Alpha DaRT platform. Bullish sentiment is heavily focused on the stock's recent technical breakout and ongoing trials, as participants emphasize the company's progress toward commercialization and the potential for a significant valuation re-rating.

Direxion Shares ETF Trust - Direxion Small Cap Bull 3X ETF

Direxion Daily Small Cap Bull 3X Shares

TNA is trending as traders analyze rotation patterns and volatility within the Russell 2000, with many in the community focusing on short-term scalping and averaging down strategies during price fluctuations. The discourse reflects a mix of sentiment regarding interest rate expectations and the index's sensitivity to macroeconomic shifts, prompting active debates on whether small-cap equities are poised for a significant breakout or continued consolidation.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is currently trending following a major, binding agreement with Yotta Data Services to deploy extensive high-performance GPU infrastructure in India, projected to generate over $500 million in revenue. Community sentiment is deeply divided, with bulls pointing to the contract as concrete proof of institutional validation and a transformative revenue catalyst, while skeptics remain vocal about concerns regarding execution transparency, historical communication gaps, and reliance on dilutive financing.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is seeing intensified investor debate as the company navigates the transition from lab-scale solid-state technology to commercial manufacturing. While community sentiment is polarized by ongoing production delays and volatility, bullish interest is being driven by the recent appointment of defense industry veteran Ross Niebergall to the board and ongoing speculation about supply chain partnerships with industrial giants like Corning.

Select Sector SPDR Trust (The) - State Street Financial Select Sector SPDR ETF

Financial Select Sector SPDR Fund

Financial stocks are experiencing a strong rally as investors pivot away from tech, with the sector hitting fresh all-time highs while breaking out of a long-term consolidation phase. The community is actively debating the durability of this leadership, with many traders closely monitoring whether financials can maintain this momentum amid shifting rate expectations and rotation out of growth sectors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Quoin is now looking to move forward with the manufacture of clinical trial and stability batches from at least one of the delivery technologies this quarter.</li><li>The company is looking to test the technologies in the treatment of microcystic lymphatic malformations and venous malformations, among others.</li><li>The company is targeting the commencement of clinical testing in the first half of 2026. &nbsp;</li></ul>&nbsp;Shares of Quoin Pharmaceuticals (QNRX) jumped as much as 39% on Tuesday after the company announced that the target loading concentrations for its two topical Rapamycin delivery technologies have been successfully achieved.A Rapamycin loading concentration of 4% w/w has been achieved for Quoin’s topical formulation, while an even higher concentration of 5% w/w has been formulated in a dermal patch system, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/11/3185408/0/en/Quoin-Pharmaceuticals-Announces-Achievement-of-Topical-Rapamycin-Target-Loadings-for-Two-Proprietary-Delivery-Technologies.html">said</a>.<h2 class="st-heading-2">Path Forward</h2>Quoin is now looking to move forward with the manufacture of clinical trial and stability batches from at least one of the delivery technologies this quarter. The company is targeting the commencement of clinical testing in the first half of 2026. &nbsp;The company is looking to test the technologies in the treatment of microcystic lymphatic malformations and venous malformations, among others. Microcystic lymphatic malformations are benign vascular anomalies characterized by a collection of small, abnormal lymphatic vessels and cysts, often appearing as small, skin-colored to pinkish or even dark, blister-like vesicles on the skin.Venous malformations, meanwhile, are present at birth, but not always visible, and are the most common type of vascular malformation. They are caused by veins that have not developed normally, resulting in tangled, enlarged vessels. Symptoms can include bluish or purplish spots, swelling, and pain.Neither microcystic lymphatic malformations nor venous malformations have FDA-approved treatments.<h2 class="st-heading-2">Executive Take Away</h2>According to Quoin CEO Michael Myers, initiating clinical development in microcystic lymphatic malformations and venous malformations will be complementary to the company’s pipeline.The firm is now looking forward to the commencement of pivotal studies for QRX003 in Netherton Syndrome by the end of the year, with the help of the financing of up to $105.3 million closed in October. Quoin’s overall pipeline comprises four products in development for Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, and Scleroderma, among others.<blockquote>“We believe that rapamycin loading concentrations of 4% and 5% in these proprietary delivery systems could potentially provide competitive advantages over other topical rapamycin formulations currently in development with similar drug loadings due to the ability of our technologies to optimize delivery of the drug at the target sites.” &nbsp; - Michael Myers, CEO, Quoin.</blockquote><h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QNRX">QNRX stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘extremely high’ levels.QNRX stock is down by 59% this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/chamath-palihapitiya-talks-about-us-achilles-heel-when-it-comes-to-rare-earths/cLPdHr9REPH">Chamath Palihapitiya Talks About US' Achilles Heel When It Comes To Rare Earths</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

QNRX Stock Soared A Whopping 39% Today: What’s Driving The Relentless Rally? 

A rapamycin loading concentration of 4% w/w has been achieved for Quoin’s topical formulation, while an even higher concentration of 5% w/w has been formulated in a dermal patch system, the company said.

Equity

Quoin Pharmaceuticals (QNRX) became the top-four trending ticker on Stocktwits on Friday morning after the stock jumped nearly 300% after the company announced that it has entered into a securities purchase agreement with new healthcare-focused institutional investors, with the potential to raise $104.5 million in gross proceeds.The late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases said that this purchase agreement also includes an initial upfront funding of $16.5 million and up to an additional $88 million upon the potential cash exercise of accompanying warrants at the election of the investors.The firm added that&nbsp;the private placement was priced at a premium to the company’s prior day’s closing stock price. Quoin said that the financing includes participation from new healthcare-focused investors, including AIGH Capital Management, Soleus Capital, Nantahala Capital, Diadema Partners, Stonepine Capital Management, ADAR1 Capital Management, and Velan Capital, among others.Retail sentiment on <a href="https://stocktwits.com/symbol/QNRX">Quoin</a> jumped to ‘extremely bullish’ from ‘bearish’ territory compared to a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.Quoin said it will issue an aggregate of 1,993,940 American Depository Shares (ADSs) and accompanying warrants to purchase up to an aggregate of 7,975,760 ADSs, at a combined purchase price of $8.25 per ADS and accompanying warrants.The company said it intends to use the upfront net proceeds for general corporate purposes, which may include operating expenses, research and development, including completion of clinical development of QRX003 for Netherton Syndrome, working capital, future acquisitions, and general capital expenditures.&nbsp;The aggregate net proceeds are expected to be sufficient to fund the company into 2027. Shares of Quoin have gained nearly 41% this year and have jumped 76% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/kalshi-doubles-valuation-to-5-b-in-latest-funding-round-report/ch6aClnR3SM">Kalshi Doubles Valuation To $5B In Latest Funding Round: Report</a>

QNRX Stock Soars 300% After $104.5M Financing Through Private Placement

Quoin said that the purchase agreement also includes an initial upfront funding of $16.5 million and up to an additional $88 million upon the potential cash exercise of accompanying warrants at the election of the investors.

Shares of Quoin Pharmaceuticals saw increased retail chatter on Wednesday after the company announced positive initial clinical data from its ongoing investigational new drug Pediatric Peeling Skin Syndrome (PSS) study evaluating QRX003.Twelve weeks of treatment produced a clear improvement in the patient's skin condition compared to initial baseline measurements.&nbsp;The stock closed at $7.65 on Wednesday, rising 20.3% during the day, but slipped 8% to $7.04 in after-hours trading.Clinical endpoints such as The Investigator's Global Assessment (IGA), Modified Ichthyosis Area Severity Index (M-IASI), and Children's Dermatology Life Quality Index (CDLQI) showed positive changes.&nbsp;The patient's IGA score changed from severe to mild, M-IASI decreased from 36 to 12, and CDLQI, the quality of life measure, fell from 19 to 11. The study reported no adverse events while administering QRX003 to patients.Quoin will extend the patient's treatment while performing additional clinical evaluations after 24 weeks of therapy.&nbsp;The firm continues to progress QRX003 through late-stage clinical trials targeting Netherton Syndrome, another uncommon skin condition.Peeling Skin Syndrome is a rare genetic disorder that manifests through excessive outer skin shedding, leading to persistent pain and itching.&nbsp;Without any existing approved treatments, the promising results from QRX003 trials suggest its potential importance if future studies confirm the positive outcomes.CEO Michael Myers stressed the clinical importance of observed improvements and pointed out QRX003's potential to become the first approved therapy for PSS, noting plans to expand the study internationally.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 2,314% surge in 24-hour message volume.One user noted that some investors with less conviction tend to sell just before market close, expressing hope that the stock would open at $20.&nbsp;<stembedurl>https://stocktwits.com/89gt/message/614698425</stembedurl>Another user highlighted the stock’s potential for rapid movement due to its very low float and recent positive news.<stembedurl>https://stocktwits.com/MasterofThePennies/message/614637863</stembedurl>The stock has declined 67.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Buzz Intensifies Around Quoin Pharma Stock After Positive Pediatric Skin Study Data

The stock closed up 20% on Wednesday, driven by promising patient outcomes and no reported adverse events for its Pediatric Peeling Skin Syndrome (PSS) drug, with further treatment and evaluations planned.

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

QNRX
Quoin Pharmaceuticals Ltd - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest QNRX News

QNRXQuoin Pharmaceuticals Ltd - ADR